# US 2023/0406946 A1 · Antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406946 A1
- Document ID: US20230406946A1
- Status: Published application
- Kind: A1
- Application number: 17/821,302
- Filed: 2022-08-22
- Published: 2023-12-21
- Earliest claimed: 2015-12-02
- Assignees: Agenus Inc.; Memorial Sloan Kettering Cancer Center; Ludwig Institute for Cancer Research
- Applicants: Agenus Inc.; Memorial Sloan-Kettering Cancer Center; Ludwig Institute for Cancer Research Ltd.
- Inventors: Nicholas S. WILSON; Jeremy D. WAIGHT; Gerd RITTER; David SCHAER; Daniel HIRSCHHORN-CYMERMAN; Taha MERGHOUB; Ekaterina V. BREOUS-NYSTROM; Volker SEIBERT; Takemasa TSUJI; Olivier LÉGER; Dennis J. UNDERWOOD; Marc VAN DIJK
- Web page: https://patentgrep.com/patent/US20230406946A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/31: multispecific
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.

## Claims

### Claim at position 1

-188. (canceled)

### Claim 189

A method for detecting cells expressing GITR and OX40 in a sample comprising contacting the sample with a multispecific antibody comprising a first antigen-binding region that specifically binds human OX40 and a second antigen-binding region that specifically binds human GITR, wherein:
a. the first antigen-binding region comprises a first heavy chain comprising CDRs VH-CDR1, VH-CDR2, and VH-CDR3, and a first light chain comprising CDRs VL-CDR1, VL-CDR2, and VL-CDR3, wherein the first heavy chain comprises the VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences of the VH amino acid sequence of SEQ ID NO:54, and the first light chain comprises the VL-CDR1, VL-CDR2, and VL-CDR3 amino acid sequences of the VL amino acid sequence of SEQ ID NO:55; and
b. the second antigen-binding region comprises a second antibody heavy chain comprising CDRs VH-CDR1, VH-CDR2, and VH-CDR3 and a second antibody light chain comprising CDRs VL-CDR1, VL-CDR2, and VL-CDR3, wherein:
i. the VH-CDR1 comprises the amino acid sequence of X1YX2MX3 (SEQ ID NO:87), wherein X1 is D, E or G; X2 is A or V; and X3 is Y or H;
ii. the VH-CDR2 comprises the amino acid sequence of X1IX2TX3SGX4X5X6YNQKFX7X8 (SEQ ID NO:88), wherein X1 is V or L; X2 is R, K or Q; X3 is Y or F; X4 is D, E or G; X5 is V or L; X6 is T or S; X7 is K, R or Q; and X8 is D, E or G;
iii. the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:3;
iv. the VL-CDR1 comprises the amino acid sequence of KSSQSLLNSX1NQKNYLX2 (SEQ ID NO:90), wherein X1 is G or S; and X2 is T or S;
v. the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:5; and
vi. the VL-CDR3 comprises the amino acid sequence of QNX1YSX2PYT (SEQ ID NO:92), wherein X1 is D or E; and X2 is Y, F or S.

### Claim 190 (depends on 189)

The method of claim 189, wherein:
a. the VH-CDR1 of the first antigen-binding region comprises the amino acid sequence of SEQ ID NO:47;
b. the VH-CDR2 of the first antigen-binding region comprises the amino acid sequence of SEQ ID NO:48;
c. the VH-CDR3 of the first antigen-binding region comprises the amino acid sequence of SEQ ID NO:49;
d. the VL-CDR1 of the first antigen-binding region comprises the amino acid sequence of SEQ ID NO:50;
e. the VL-CDR2 of the first antigen-binding region comprises the amino acid sequence of SEQ ID NO:51; and
f. the VL-CDR3 of the first antigen-binding region comprises the amino acid sequence of SEQ ID NO:52 or SEQ ID NO:53.

### Claim 191 (depends on 189)

The method of claim 189, wherein the first antigen-binding region comprises a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:52.

### Claim 192 (depends on 189)

The method of claim 189, wherein the first antigen-binding region comprises a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:53.

### Claim 193 (depends on 189)

The method of claim 189, wherein:
a. (i) the VH-CDR1 of the second antigen-binding region comprises the amino acid sequence of X1YAMX2 (SEQ ID NO:1), wherein X1 is D, G, or E; and X2 is Y or H;
(ii) the VH-CDR2 of the second antigen-binding region comprises the amino acid sequence of X1IRTYSGX2VX3YNQKFX4X5(SEQ ID NO:2), wherein X1 is V or L; X2 is D or G; X3 is T or S; X4 is K, R, or Q; and X5 is D, E, or G; (iii) the VH-CDR3 of the second antigen-binding region comprises the amino acid sequence of SEQ ID NO:3; (iv) the VL-CDR1 of the second antigen-binding region comprises the amino acid sequence of KSSQSLLNSX1NQKNYLT (SEQ ID NO:4), wherein X1 is G or S;
(v) the VL-CDR2 of the second antigen-binding region comprises the amino acid sequence of SEQ ID NO:5; and (vi) the VL-CDR3 of the second antigen-binding region comprises the amino acid sequence of QNX1YSX2PYT (SEQ ID NO:6), wherein X1 is D or E; and X2 is Y or F;
b. the VH-CDR1 of the second antigen-binding region comprises the amino acid sequence of SEQ ID NO:7, 8, or 9;
c. the VH-CDR2 of the second antigen-binding region comprises the amino acid sequence of SEQ ID NO:10, 11, 12, or 13;
d. the VL-CDR1 of the second antigen-binding region comprises the amino acid sequence of SEQ ID NO:14 or 15;
e. the VL-CDR3 of the second antigen-binding region comprises the amino acid sequence of SEQ ID NO:16 or 17;
f. the VH-CDR1, the VH-CDR2, and the VH-CDR3 of the second antigen-binding region comprise the amino acid sequences of SEQ ID NOs:7, 10, and 3; 8, 11, and 3; 9, 12, and 3; or 9, 13, and 3, respectively; and/or the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the second antigen-binding region comprise the amino acid sequences of SEQ ID NOs:14, 5, and 16; or 15, 5, and 17, respectively; or
g. the VH-CDR1, the VH-CDR2, the VH-CDR3, the VL-CDR1, the VL-CDR2, and the VL-CDR3 of the second antigen-binding region comprise the amino acid sequences of SEQ ID NOs:7, 10, 3, 14, 5, and 16, respectively.

### Claim 194 (depends on 189)

The method of claim 189, wherein:
a. the VH of the first antigen-binding region comprises an amino acid sequence that is at least 75% identical to the amino acid sequence of SEQ ID NO:54;
b. the VH of the first antigen-binding region comprises the amino acid sequence of SEQ ID NO:54;
c. the VH of the first antigen-binding region comprises an amino acid sequence derived from a human IGHV3-73 germline sequence;
d. the VL of the first antigen-binding region comprises an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:55 or SEQ ID NO:56;
e. the VL of the first antigen-binding region comprises the amino acid sequence of SEQ ID NO:55 or 56;
f. the VL of the first antigen-binding region comprises an amino acid sequence derived from a human IGKV2-28 germline sequence;
g. the VH and the VL of the first antigen-binding region comprise the amino acid sequences of SEQ ID NOs:54 and 55; or 54 and 56, respectively; or
h. the VH of the first antigen-binding region comprises an amino acid sequence derived from a human IGHV3-73 germline sequence and a VL comprising an amino acid sequence derived from a human IGKV2-28 germline sequence.

### Claim 195 (depends on 189)

The method of claim 189, wherein:
a. the VH of the second antigen-binding region comprises the amino acid sequence of SEQ ID NO:25;
b. the VH of the second antigen-binding region comprises an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:18, 20, 22, or 24;
c. the VH of the second antigen-binding region comprises the amino acid sequence of SEQ ID NO:18, 20, 22, or 24;
d. the VH of the second antigen-binding region comprises an amino acid sequence derived from a human IGHV1-2 germline sequence;
e. the VL of the second antigen-binding region comprises the amino acid sequence of SEQ ID NO:26;
f. the VL of the second antigen-binding region comprises an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:19, 21, or 23;
g. the VL of the second antigen-binding region comprises the amino acid sequence of SEQ ID NO:19, 21, or 23;
h. the VL of the second antigen-binding region comprises an amino acid sequence derived from a human IGKV4-1 germline sequence;
i. the VH and the VL of the second antigen-binding region comprise the amino acid sequences of SEQ ID NOs:18 and 19; 20 and 21; 22 and 23; or 24 and 23, respectively; or
j. the VH of the second antigen-binding region comprises an amino acid sequence derived from a human IGHV1-2 germline sequence and a VL comprising an amino acid sequence derived from a human IGKV4-1 germline sequence.

### Claim 196 (depends on 189)

The method of claim 189, wherein:
a. the first heavy chain comprises the amino acid sequence of SEQ ID NO:59, 60, 66, 118, 119, or 125;
b. the first light chain comprises the amino acid sequence of SEQ ID NO:67, 68, 69, or 70;
c. the first heavy chain comprises the amino acid sequence of SEQ ID NO:59 and the first light chain comprises the amino acid sequence of SEQ ID NO:67 or 69; or
d. the first heavy chain comprises the amino acid sequence of SEQ ID NO:118 and the first light chain comprises the amino acid sequence of SEQ ID NO:67 or 69.

### Claim 197 (depends on 189)

The method of claim 189, wherein:
a. the second heavy chain comprises the amino acid sequence of SEQ ID NO:29, 30, 36, 74, 74, or 81;
b. the second light chain comprises the amino acid sequence of SEQ ID NO:37 or 38;
c. the second heavy chain comprises the amino acid sequence of SEQ ID NO:29 and the second light chain comprises the amino acid sequence of SEQ ID NO:37;
d. the second heavy chain comprises the amino acid sequence of SEQ ID NO:74 and the second light chain comprises the amino acid sequence of SEQ ID NO:37;
e. the second heavy chain comprises the amino acid sequence of SEQ ID NO:30 and the second light chain comprises the amino acid sequence of SEQ ID NO:37; or
f. the second heavy chain comprises the amino acid sequence of SEQ ID NO: 75 and the second light chain comprises the amino acid sequence of SEQ ID NO:37.

### Claim 198 (depends on 189)

The method of claim 189, wherein the antibody further comprises a detectable label.

### Claim 199 (depends on 189)

The method of claim 189, wherein the first heavy chain and/or the second heavy chain comprises a heavy chain constant region selected from the group consisting of human IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

### Claim 200 (depends on 199)

The method of claim 199, wherein the first heavy chain and/or the second heavy chain comprises an IgG1 heavy chain constant region.

### Claim 201 (depends on 200)

The method of claim 200, wherein:
a. the first heavy chain comprises serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, and the second heavy chain comprises tryptophan at amino acid position 366; or
b. the first heavy chain comprises tryptophan at amino acid position 366, and the second heavy chain comprises serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, numbered according to the EU numbering system.

### Claim 202 (depends on 201)

The method of claim 201, wherein the first heavy chain and/or the second heavy chain comprises aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively, numbered according to the EU numbering system.

### Claim 203 (depends on 189)

The method of claim 189, wherein the first light chain and/or the second light chain comprises a human kappa light chain constant region or a human lambda light chain constant region.

### Claim 204 (depends on 200)

The method of claim 200, wherein:
a. the first heavy chain comprises the amino acid sequence of SEQ ID NO:54, and the first light chain comprises the amino acid sequence of SEQ ID NO:67; and
b. the second heavy chain comprises the amino acid sequence of SEQ ID NO:18, and the second light chain comprises the amino acid sequence of SEQ ID NO:37.

### Claim 205 (depends on 189)

The method of claim 189, wherein the first heavy chain comprises aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively, numbered according to the EU numbering system.

### Claim 206 (depends on 189)

The method of claim 189, wherein the second heavy chain comprises aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively, numbered according to the EU numbering system.

### Claim 207 (depends on 189)

The method of claim 189, wherein the first heavy chain and the second heavy chain comprise aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively, numbered according to the EU numbering system.

### Claim 208 (depends on 199)

The method of claim 199, wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 126.
